Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04759742
Other study ID # Arthroscopic anesthesia
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date March 1, 2021
Est. completion date June 1, 2023

Study information

Verified date August 2023
Source Shengjing Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fast-track Surgery (FTS ) refers to the application of various proven effective methods in perioperative period to reduce stress and complications and accelerate the recovery of patients.Nowadays, FTS has been successfully applied in clinical practice."FTS" truly embodies the concept of "patient-centered" and the direction of medical development. Lower limb joint damage (the meniscus, and patellar ligament, etc.) is the joint movement orthopedic common disease, often characterized by joint swelling, pain, sports relaxation instability, thigh muscle atrophy, most can't continue to pursue the original movement, even unbend and flexor limited activity, result in patients with walking difficulties, serious impact on the patient's quality of life.Practice has proved that minimally invasive surgery under arthroscopy is the best way to treat such injuries. According to literature reports, the average hospital stay after arthroscopy is 5~7 days, while successful application of FTS can shorten it to 2~3 days. Anesthesia plays an important role in the process of FTS.Compared with general anesthesia, intra-spinal anesthesia can effectively reduce the incidence of postoperative complications in patients, such as ventilator-related lung injury, deep vein thrombosis, cardiovascular and cerebrovascular accidents, and acute renal failure.Ropivacaine is a long-acting amide local anesthetic. Compared with bupivacaine, it is more and more widely used in spinal anesthesia due to its advantages of lower degree of motor nerve block and weaker toxicity to central nervous system and cardiac.However, the optimal dosage of ropivacaine for arthroscopic surgery is still unclear. Conventional dosage makes patients unable to move 2-4h after surgery and unable to urinate autonomically. Therefore, this study aims to optimize the dosage of ropivacaine for spinal anesthesia and enable patients to recover motor function at an early stage.


Recruitment information / eligibility

Status Completed
Enrollment 115
Est. completion date June 1, 2023
Est. primary completion date June 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patients undergoing elective arthroscopic knee surgery - ASA: grade I to III Exclusion Criteria: - There are contraindications to spinal anesthesia - Allergic to local anesthetics - Patient refused

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ropivacaine
According to previous clinical experience, 0.5% ropivacaine was given in the subarachnoid cavity, and the initial dose was set at 2.5 mL (12.5mg). Dixon's up-and down method was adopted to adjust or down-adjust the dose of ropivacaine in the next patient according to the experimental results of the previous patient, and the adjusted dose was 0.1 mL (0.5mg).

Locations

Country Name City State
China Shengjing Hospital Shengyang Liaoning

Sponsors (1)

Lead Sponsor Collaborator
Yanchao Yang

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the median effective dose (ED) of ropivacaine in knee arthroscopic surgery The primary outcome of this present study was the median effective dose (ED) of ropivacaine in knee arthroscopic surgery to allow immediate postoperative mobilization as well as adequate anesthesia during surgery.The up and down method as described by Dixon and Massey was used.This is a sequential allocation model in which patients received a dose of ropivacaine according to the outcome of the preceding patient. A starting dose of the test sequence was set to 12.5 mg ropivacaine .The dose of ropivacaine in the next patient was increased or decreased according to the experimental results of the previous patient, and the adjusted dose was 0.5mg. from preoperative to postoperative 24 hours
See also
  Status Clinical Trial Phase
Completed NCT03688269 - Minimal Effective Concentration (EC90) of Ropivacaine Phase 3
Not yet recruiting NCT06145945 - Effect of Intraperitoneal Ropivacaine on Visceral Pain After Laparoscopic Gastrectomy N/A
Recruiting NCT06430112 - Liposomal Bupivacaine vs Ropivacaine for TAPBs Phase 3
Recruiting NCT02125994 - Effect of 0.5% vs 0.375% Ropivacaine on Autonomous Nervous System N/A
Not yet recruiting NCT04763434 - Dexamethasone and Dexmedetomidine as Adjuvants to Ropivacaine in Ultrasound-guided Multilevel Thoracic Paravertebral Block for Lobectomy: A Prospective, Randomized, Triple-blind Study Phase 4
Completed NCT05995301 - Comparative Study on Postoperative Analgesia With Transversus Abdominis Plane Block to Local Anesthetic Infiltration With Ropivacaine in Laparoscopic Abdominal Surgery N/A
Completed NCT05979558 - Caudal Ropivacaine With or Without Dexmedetomidine for Post Operative Analgesia N/A
Recruiting NCT02838329 - Labour Epidural Top-up With Warmed Ropivacaine N/A
Completed NCT02344264 - Effect of Nervus Cutaneous Femoris Lateralis-Blockade on Moderate Pain Responders After Total Hip Arthroplasty Phase 4
Not yet recruiting NCT05824338 - Testing the Feasibility of Using Ropivacaine in Spinal Anesthesia for Patients With Lower Back Surgery Early Phase 1
Recruiting NCT04879004 - EFFECT - EFFectiveness of ESPB (Erector Spinae Plane Block) in Laparoscopic Cοlectomies Trial N/A
Completed NCT03563963 - Ropivacaine vs Lidocaine in the Endotracheal Tube Cuff on Post-Operative Sore Throat N/A
Recruiting NCT06379490 - Ultrasound-guided Infraclavicular Block With Lidocaine or Ropivacaine for Closed Reduction of Distal Radius Fractures Phase 3
Completed NCT03265223 - Ropivacaine Use Intraincisionally Versus Intraperitoneally for Post-Laparoscopic Cholecystectomy Pain Phase 4